Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquired |
gptkb:Daiichi_Sankyo
|
| gptkbp:acquisition |
gptkb:2011
|
| gptkbp:ceo |
Peter H. H. Hwang
|
| gptkbp:clinical_trial |
ongoing
Phase II completed Phase III Phase I Phase I/ II Phase II/ III |
| gptkbp:collaborations |
gptkb:Genentech
gptkb:Bristol-Myers_Squibb academic institutions biotech companies international research groups |
| gptkbp:employees |
50-100
|
| gptkbp:focus |
drug discovery
solid tumors hematologic malignancies |
| gptkbp:founded |
gptkb:2001
|
| gptkbp:founder |
gptkb:James_E._Mc_Gowan
|
| gptkbp:headquarters |
gptkb:Berkeley,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Plexxikon
|
| gptkbp:invention |
over 100
|
| gptkbp:investment |
institutional investors
private equity firms |
| gptkbp:language_of_instruction |
multiple drug candidates
|
| gptkbp:notable_products |
gptkb:Zydelig
|
| gptkbp:partnership |
gptkb:temple
gptkb:Pfizer |
| gptkbp:platform |
personalized medicine
targeted therapies biologics combination therapies novel targets |
| gptkbp:publishes |
numerous
|
| gptkbp:receives_funding_from |
gptkb:Company
public offerings |
| gptkbp:regulatory_compliance |
FDA approved drugs
EMA approved drugs |
| gptkbp:research_areas |
oncology
autoimmune diseases inflammation neurological disorders cardiovascular diseases infectious diseases metabolic diseases |
| gptkbp:technology |
structure-based drug design
small molecule therapeutics |
| gptkbp:website |
www.plexxikon.com
|
| gptkbp:bfsParent |
gptkb:IDXX
|
| gptkbp:bfsLayer |
4
|